Cytovance Biologics Selected for GMP Manufacture of AM0010
News Jul 01, 2014
Cytovance Biologics has announced successful completion of GMP manufacture of ARMO BioSciences’ lead product, AM0010, a PEGylated form of recombinant human interleukin-10 (IL-10).
“Cytovance is proud to have been an integral partner in the manufacture of AM0010 bulk drug substance and drug product,” states Darren Head, President and Chief Executive Officer of Cytovance Biologics. “Our team responded to the urgency to get this important drug to patients with advanced solid tumors.”
“Cytovance’s responsive and professional team enabled us to accelerate the time to clinic of AM0010 which is currently in a Phase 1 dose escalation study in patients with cancer,” said Peter Van Vlasselaer, Ph.D., President and Chief Executive Officer of ARMO. “We look forward to continuing our relationship with Cytovance as the manufacturer of product in support of the clinical development of AM0010.”
“Cytovance’s state-of-the-art facilities and staff are prepared to deliver the highest quality of manufacturing services for ARMO,” adds Darren Head.
Head continued, “We are delighted to work with ARMO. Their fast pace and rigorous scientific know-how are a good match for Cytovance’s sense of urgency and flexibility. Together, we can produce high quality material for patients quickly and efficiently in a cost-efficient manner.”
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019